According to a post to the FDA website, is now indicated for the treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; and steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older
https://thefly.com/landingPageNews.php?id=2913967
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.